WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR May 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: MAY ISSUE PUBLISHED

    MAY 2024 Issue has been successfully launched on MAY 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

EFFECTIVE MANAGEMENT OF MENORRHAGIA WITH AN AYURVEDIC NON-HORMONAL FORMULATION ‘VEERHA’- A CLINICAL STUDY

Dr. Aarati Patil, *Dr. Kshitija Berde and Dr Priyanka Tekale

ABSTRACT

Menstruation is a crucial factor in determining women’s health. Worldwide, menstrual disturbances and associated problems are rising rapidly. Menorrhagia is a common symptom in women referring to heavy or prolonged bleeding, which arises due to various underlying disease conditions. Although various approaches to management are available, irrational selection of treatment is prevalent. The present study is an open-label, single center, non-comparative, retrospective clinical study. This study was aimed to evaluate the efficacy of a non-hormonal Ayurvedic proprietary formulation ‘Veerha’ containing ingredients like Ashoka (Saraca asoca), Lodhra (Symplocos racemosa), Musta (Cyperus rotundus), Kramuka (Areca catechu), Mocharasa (Bombax ceiba), Shatavari (Asparagus racemosus), etc. in menorrhagia. A total of 90 patients suffering from heavy, prolonged or heavy and prolonged menses falling in the age group of 21-50 years and fulfilling all the inclusion criteria were considered for the study. Patients diagnosed with serious gynecological conditions like endometriosis, adenomyosis, etc. were excluded from the study. Four tablets of Veerha (1g each) were administered daily with water for three consecutive months. The patients were followed up after completion of three months to assess amount of bleeding, period of bleeding, etc. 75.94% patients reported reduced bleeding and 55.17% patients reported shortened period length. Associated complaints like dysmenorrhea, passage of blood clots also showed significant improvement. The p value was found to be less than 0.05. The results were statistically as well as clinically significant. No adverse events or adverse drug reactions were noted during the study. All the patients tolerated the medicine well and none experienced worsening of the condition.

[Full Text Article] [Download Certificate]